Skip to main content
ABL Bio Inc. logo

ABL Bio Inc. — Investor Relations & Filings

Ticker · 298380 ISIN · KR7298380007 LEI · 9884007BRC71Y64NK235 KO Professional, scientific and technical activities
Open in API
Filings indexed 369 across all filing types
Latest filing 2019-12-17 Regulatory Filings
Country KR South Korea
Listing KO 298380

About ABL Bio Inc.

https://www.ablbio.com

ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.

Recent filings

Filing Released Lang Actions
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the closure of the shareholder register for the purpose of determining shareholders eligible to vote at the upcoming Annual General Meeting (AGM). It does not contain the full AGM materials or proxy statements, but rather serves as a formal regulatory notice of a corporate action. Given it is a specific regulatory announcement that does not fit into the other categories, it is classified as a Regulatory Filing.
2019-12-17 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 95% confidence The document is a short announcement (under 1,000 characters) notifying the public about an upcoming Investor Relations (IR) event (기업설명회). It provides the date, time, location, and purpose of the meeting, and mentions that the presentation materials will be available on the KRX KIND system. Since it is an announcement of an event rather than the presentation slides themselves, and it serves as a regulatory notification of a corporate event, it fits the criteria for a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given the specific nature of announcing an IR event, RPA is the most accurate classification.
2019-11-20 Korean
분기보고서 (2019.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for ABL Bio, covering the period from January 1, 2019, to September 30, 2019. It contains detailed corporate information, financial data, management discussion, and business operations, which aligns with the definition of an Interim/Quarterly Report (IR). It is not a mere announcement or certification, as it provides substantive financial and operational disclosures. 9M 2019
2019-11-14 Korean
기업설명회(IR)개최
Regulatory Filings Classification · 95% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (Non-Deal Roadshow). It provides the date, location, purpose, and method of the event. Since it is an announcement of an event rather than the presentation slides themselves, and it fits the criteria for a regulatory announcement regarding corporate activities, it is classified as a Regulatory Filing (RNS).
2019-09-23 Korean
기업설명회(IR)개최
Regulatory Filings Classification · 95% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event, specifically a Non-Deal Roadshow (NDR) for institutional investors. It provides details such as date, location, purpose, and the method of dissemination for IR materials. Since it is an announcement of an event and the availability of materials rather than the presentation deck itself, it falls under the category of a regulatory filing or announcement regarding corporate activities.
2019-09-06 Korean
기업설명회(IR)개최
Regulatory Filings Classification · 95% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (a corporate presentation at the Morgan Stanley Global Healthcare Conference). It provides details such as date, location, purpose, and method of the meeting. Since it is an announcement of an event rather than the presentation slides themselves, and it serves as a regulatory notification of corporate activity, it fits best under the 'Regulatory Filings' (RNS) category as it is a standard disclosure of an IR event schedule.
2019-09-06 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.